Xenon Pharmaceuticals Inc.

Switch Materials, Inc.

Dermira (Canada), Inc.

Valocor Therapeutics, Inc.

Novartis Ag

Qlt Inc.

Solutia Canada Inc.

Kinetek Pharmaceuticals, Inc.

Dirmira (Canada), Inc.

Olt Inc.

Serguei Sviridov

Zaihui Zhang

Shaoyi Sun

Rajender Kamboj

Shifeng Liu

Jianmin Fu

Vishnumurthy Kodumuru

Nagasree Chakka

Sultan Chowdhury

Mikhail A Chafeev

Vandna Raina

Duanjie Hou

Melwyn A Abreo

Jianyu Sun

Michael D Winther

Heinz W Gschwend

Simon James Gauthier

Timothy Scott Daynard

Shisen Wang

Chi Tu

Xinyao Du

Gregory B Chopiuk

Neil Robin Branda

Alla Yurevna Zenova

Mark W Holladay

Jeremy Graham Finden

Mark Wood

Daniel F Harvey

Qi Jia

Jianxin Chen

Jean-Jacques Alexandre Cadieux

Jian-Min Fu

Natalia Pokrovskaia

Duhane Lam

Natalie Alysia Dales

Wenbao Li

Mehran Seid Bagherzadeh

Tom Hsieh

Jonathan David Langille

Ali Hayek

Andreea Spantulescu

Mikhail Kondratenko

Kyle Andrew Hope-Ross

Lauren Fraser

Robert Fraser

James Daniel Senior

Jun Yan

Zoran Cikojevic

Amy Frances Douglas

Sengen Sun

Cindy J Hudson

Mehran Bagherzadeh

Kashinath Sadalapure

Greg Chopiuk

Shifeng Lui

Heinz Gschwend

Michael Winther

Sun Shaoyi

Kashinath Sadalupure

Rajender K Kamboj

Mikhail Chafev

Jian-min Fu

Mikhail A Kondratenko

A compound according to Formula IA and IB, reversibly convertible under photochromic and electrochromic conditions between a ring-open isomer A and a ring-closed isomer B is provided. For substitutent groups, Z is N, O or S; each Ris independently selected from the group consisting of H, or halo; each Ris independently selected from the group consisting of H, halo, a polymer backbone, alkyl or aryl; or, when both Rtogether form &#x2014;CH&#x2550;CH&#x2014; and form part of a polymer backbone; each Ris independently selected from the group consisting of H, halo, alkyl, alkoxy, thioalkyl or aryl; each Ris aryl; and each Ris independently selected from the group consisting of H, halo, alkyl, alkoxy, thioalkyl or aryl. 

Diarylethene compounds and uses thereof

This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro-oxindole compounds and their use as therapeutic agents

Topical formulations and method of using the same are provided. The topical formulation comprises a pyrazolylbenzothiazole derivative of the following formula (1) wherein X, R, R, Rand Rare described herein.

Pyrazolylbenzothiazole derivatives and their use as therapeutic agents

Variable transmittance optical filters capable of transitioning from a light state to a dark state on exposure to UV radiation and from a dark state to a light state with application of an electric voltage are provided. The optical filters comprise a switching material that comprises one or more chromophores that have electrochromic and photochromic properties.

Variable transmittance optical filter and uses thereof

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where V, W, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R, R, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer. 

Use of spiro-oxindole compounds as therapeutic agents

Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

Hydrazonopyrazole derivatives and their use as therapeutics

Spiro-oxindole compounds and their uses as therapeutic agents

Pharmaceutical compositions and compounds are provided. The compounds of the invention have use as therapeutic agents, e.g., they demonstrate anti-proliferative, anti-inflammatory, anti-angiogenic, anti-migration activities. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of, e.g., anti-inflammatory, renal, and hyperproliferative disorders. The compounds of the invention are pyrazolylbenzothiazole derivatives of the following formula (1) wherein X, R, R, Rand Rare described herein.

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): 

Pyridyl derivatives and their use as therapeutic agents

Growing community of inventors

Burnaby, Canada

Serguei Sviridov